search  
 


Home

Who are we?

Why
register?


Signup for
registration


Online registration

Log in to register
your trial


Search a trial

NRT en CCMO

Contact

NEDERLANDS





MetaRegister
van CCT (UK)


ISRCTN-Register
van CCT (UK)


Metabolic effects of Diabecinn (oral cinnamon extract) in diabetes type 2, a placebo-controlled randomized clinical trial.


- candidate number2031
- NTR NumberNTR635
- ISRCTNISRCTN36704940
- Date ISRCTN created28-apr-2006
- date ISRCTN requested25-apr-2006
- Date Registered NTR21-mrt-2006
- Secondary IDsN/A 
- Public TitleMetabolic effects of Diabecinn (oral cinnamon extract) in diabetes type 2, a placebo-controlled randomized clinical trial.
- Scientific TitleMetabolic effects of Diabecinn (oral cinnamon extract) in diabetes type 2, a placebo-controlled randomized clinical trial.
- ACRONYMDiabecinn trial
- hypothesisThe main objective of this randomized, placebo-controlled trial is to determine the effects of cinnamon extract on HbA1c and lipid profiles in type 2 diabetic patients.
- Healt Condition(s) or Problem(s) studiedDiabetes Mellitus Type 2 (DM type II)
- Inclusion criteria1. Type 2 diabetes patients;
2. Age 35-70 years inclusive;
3. HbA1c between 7 and 12% inclusive.
- Exclusion criteria1. Pregnancy;
2. Breast-feeding.
- mec approval receivedyes
- multicenter trialyes
- randomisedyes
- masking/blindingDouble
- controlPlacebo
- groupParallel
- Type2 or more arms, randomized
- Studytypeintervention
- planned startdate 1-mei-2006
- planned closingdate1-jan-2007
- Target number of participants120
- InterventionsDiabecinn tid or placebo.
- Primary outcomeHbA1c.
- Secondary outcome1. Lipid profile;
2. 6 point glucose profile;
3. Hypoglycemia;
4. Body weight;
5. Free fatty acids;
6. CRP.
- TimepointsN/A
- Trial web siteN/A
- statusstopped
- CONTACT FOR PUBLIC QUERIESMD. PhD. J.H. DeVries
- CONTACT for SCIENTIFIC QUERIESMD. PhD. J.H. DeVries
- Sponsor/Initiator Academic Medical Center (AMC), Amsterdam
- Funding
(Source(s) of Monetary or Material Support)
OTC Pharma
- PublicationsN/A
- Brief summaryDiabetes is a disease characterized by abnormalities in both lipid and glucose metabolism. In a placebo controlled study reported by Khan, 15 to 25% reductions in fasting glucose, total and LDL cholesterol and triglycerides were seen after 40 days of treatment. While these results are very promising, a trial with longer duration and a widely accepted measure of overall glucose homeostasis, i.e. HbA1c, is needed.
- Main changes (audit trail)
- RECORD21-mrt-2006 - 21-nov-2009


  • Indien u gegevens wilt toevoegen of veranderen, kunt u een mail sturen naar nederlands@trialregister.nl